Perspectives of commissioners and cancer specialists in prioritising new cancer drugs: impact of the evidence threshold

被引：28

作者：

Foy, R

So, J

Rous, E

Scarffe, JH

机构：

[1] Stockport Hlth Author, Stockport SK7 5BY, England

[2] Christie Hosp NHS Trust, Manchester M20 4BX, Lancs, England

来源：

关键词：

D O I：

10.1136/bmj.318.7181.456

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：456 / 459

页数：6

共 25 条

[1]

*AC MED ROYAL COLL, 1997, PRIOR SETT NHS DISC

[2] Fludarabine in chronic leukaemia [J].

Astrow, AB .

[3]

*AUD COMM, 1997, HIGH PURCH COMM SPEC

[4] Commissioning specialist services in the NHS [J].

Black, N .

[5]

Bower H, 1997, BRIT MED J, V314, P466

[6]

BUZDAR A, 1997, P AN M AM SOC CLIN, V16, P156

[7]

Calman K, 1995, POLICY FRAMEWORK COM, P18

[8]

Chan S, 1997, Oncology (Williston Park), V11, P19

[9]

CHUSTECKA Z, 1998, SCRIP, V2338, P28

[10]

Collins H.M., 1993, The golem : what everyone should know about science